Patients in the EU with Fanconi anaemia (FA) could soon have the first gene therapy option for the disorder, as the EMA starts a review of Rocket Pharma’s RP-L102 candidate. FA is an inherited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback